![Joseph Klein](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 850 221 $ al 31/05/2026
Joseph R.
Klein is the founder of Gauss Capital Advisors LLC, serving as Managing Director since 1998.
Current jobs include Independent Director at Ionis Pharmaceuticals, Inc. since 2005, Director at Shire Regenerative Medicine, Inc., and Director at Prospector Funds, Inc. since 2007.
Former jobs include Director at Savient Pharmaceuticals, Inc., Director at OSI Pharmaceuticals, Inc. from 2006 to 2010, Director at Clinical Data, Inc. in 2006, Director at Synbiotics LLC, Director at NPS Pharmaceuticals, Inc. from 1998 to 2007, Director at Guilford Pharmaceuticals, Inc. from 1998 to 2005, Director at BioMarin Pharmaceutical, Inc. from 2005 to 2010, Director at Genaissance Pharmaceuticals, Inc. in 2005, Director at BioMarker Strategies LLC, Non-Executive Director at Gliknik, Inc., Director at PDL BioPharma, Inc. from 2007 to 2010, Director at Akcea Therapeutics, Inc. from 2019 to 2020, Vice President at T.
Rowe Price Associates, Inc. from 1989 to 1998, Portfolio Manager at Kaufmann Fund, Inc., Vice President-Strategy at Medical Manager Corp.
from 1999 to 2000, Partner at MPM BioImpact LLC from 2001 to 2002, Analyst at Federated Investment Management Co. in 1999, and Venture Partner at Red Abbey Venture Partners LLC from 2003 to 2008.
Education includes an MBA from Stanford University and an undergraduate degree from Yale University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 01/05/2026 | 11.114 ( 0,01 % ) | 850 221 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| IONIS PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 13/12/2005 |
Prospector Funds, Inc. | Director/Miembro de la Junta | 01/09/2007 |
Shire Regenerative Medicine, Inc.
 Shire Regenerative Medicine, Inc. BiotechnologyHealth Technology Manufactures biomedical products | Director/Miembro de la Junta | 28/02/2011 |
Gauss Capital Advisors LLC
 Gauss Capital Advisors LLC Investment ManagersFinance GCA focuses on investments in the biopharmaceuticals and health technology sectors. | Fundador | 01/03/1998 |
| Empresas | Cargo | Fin |
|---|---|---|
| AKCEA THERAPEUTICS, INC. | Director/Miembro de la Junta | 12/10/2020 |
| PDL BIOPHARMA, INC. | Director/Miembro de la Junta | 01/01/2010 |
| OSI PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 03/06/2010 |
| BIOMARIN PHARMACEUTICAL INC. | Director/Miembro de la Junta | 19/03/2010 |
Red Abbey Venture Partners LLC
 Red Abbey Venture Partners LLC Investment ManagersFinance Red Abbey Venture Partners invests in companies located in North America and Europe. The firm focuses on a broad range of sectors. It participates in early and late-stage transactions. It acts as a co-investor and invests in public companies. | Inversor de Capital Privado | 01/12/2008 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 24 |
|---|---|
Savient Pharmaceuticals, Inc.
 Savient Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products | Health Technology |
OSI Pharmaceuticals, Inc.
 OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and develops pharmaceutical drugs | Health Technology |
Clinical Data, Inc.
 Clinical Data, Inc. Medical SpecialtiesHealth Technology Manufactures and distributes scientific instruments | Health Technology |
T. Rowe Price Associates, Inc. (IM)
 T. Rowe Price Associates, Inc. (IM) Investment ManagersFinance Price Associates uses a complex and multifaceted approach to investment analysis and asset management decisions. They integrate ESG factors into their investment research process. The firm focuses on the ESG factors they consider most likely to have a material impact on the performance of securities in client accounts. Price Associates also focuses on their analytical process on three areas of research: the industry, the contracts issued, and the creditworthiness of each individual issuer. | Finance |
Synbiotics LLC
 Synbiotics LLC Medical SpecialtiesHealth Technology Develops monoclonal antibody-based diagnostic and biological products | Health Technology |
NPS Pharmaceuticals, Inc.
 NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for bone and mineral disorders | Health Technology |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs used to treat neurological diseases | Health Technology |
Kaufmann Fund, Inc.
 Kaufmann Fund, Inc. Financial ConglomeratesFinance Operates a growth fund that invests in small- and mid-cap companies | Finance |
Ionis Pharmaceuticals, Inc.
 Ionis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops antisense drugs | Health Technology |
BioMarin Pharmaceutical, Inc.
 BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Genaissance Pharmaceuticals, Inc.
 Genaissance Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and uses genetic information to diagnostic and therapeutic products | Health Technology |
Medical Manager Corp.
 Medical Manager Corp. Information Technology ServicesTechnology Services Provides physician management systems | Technology Services |
Shire Regenerative Medicine, Inc.
Shire Regenerative Medicine, Inc. BiotechnologyHealth Technology Manufactures biomedical products | Health Technology |
BioMarker Strategies LLC
 BioMarker Strategies LLC Pharmaceuticals: GenericHealth Technology Develops medicines for cancer | Health Technology |
Prospector Funds, Inc. | |
Gliknik, Inc.
 Gliknik, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops biotechnology drugs for autoimmune diseases and cancer | Health Technology |
MPM BioImpact LLC
 MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Finance |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Federated Investment Management Co.
 Federated Investment Management Co. Investment ManagersFinance FIMCO offers a broad range of investment strategies, from liquidity solutions to high active share global and regional equities to active credit and private markets. Each investment team works with Responsible Investing Office personnel as they look to incorporate proprietary ESG tools and insights from our in-house engagement and stewardship team, EOS at Federated Hermes. | Finance |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Red Abbey Venture Partners LLC
Red Abbey Venture Partners LLC Investment ManagersFinance Red Abbey Venture Partners invests in companies located in North America and Europe. The firm focuses on a broad range of sectors. It participates in early and late-stage transactions. It acts as a co-investor and invests in public companies. | Finance |
PDL BioPharma, Inc.
 PDL BioPharma, Inc. BiotechnologyHealth Technology Operates as a pharmaceutical company that manufactures and wholesales prescription medicine products | Health Technology |
Gauss Capital Advisors LLC
Gauss Capital Advisors LLC Investment ManagersFinance GCA focuses on investments in the biopharmaceuticals and health technology sectors. | Finance |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for cardiometabolic lipid disorders | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
